Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 23, 2006 - Issue 2
Submit an article Journal homepage
144
Views
19
CrossRef citations to date
0
Altmetric
Articles

IRINOTECAN FOR CHILDREN WITH RELAPSED SOLID TUMORS

Toshiji Shitara Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan
, MD,
Akira Shimada Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan
, MD,
Ryoji Hanada Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
, MD,
Tadashi Matsunaga Department of Pediatric Surgery, Chiba University School of Medicine, Chiba, Japan
, MD,
Keisei Kawa Department of Hematology/Oncology, Osaka Medical Center for Maternity and Child Health, Osaka, Japan
, MD,
Hideo Mugishima Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan
, MD,
Tohru Sugimoto Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
, MD,
Jun-ichi Mimaya Department of Hematology/Oncology, Shizuoka Children's Hospital, Shizuoka, Japan
, MD,
Atsushi Manabe Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
, MD,
Masahito Tsurusawa Department of Pediatrics, Aichi Medical College, Aichi, Japan
, MD &
Yoshiaki Tsuchida Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan
, MD show all
Pages 103-110 | Received 02 Mar 2005, Accepted 01 Nov 2005, Published online: 09 Jul 2009
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 636.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.